



1 Fabrication of novel-shaped microneedles to overcome 2 the disadvantages of solid microneedles for the transdermal delivery 3 of insulin

4 Yuki Mizuno¹ · Kanae Takasawa¹ · Taichi Hanada¹ · Kyou Nakamura¹ · Kazuya Yamada¹ · Hirotada Tsubaki¹ ·
5 Masaya Hara² · Yasunori Tashiro² · Masaaki Matsuo² · Takahiro Ito¹ · Tomohiro Hikima¹

6 Accepted: 12 July 2021
7 © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021

8 Abstract

9 In this study, we fabricated two different microneedles (MNs) — semi-hollow and bird-bill — to overcome the limitations of
10 solid and coated MNs, respectively. The two MN arrays were developed using a general injection molding process to obtain
11 high-quality MNs with uniform shape. The semi-hollow and bird-bill MNs could penetrate the micropores of swine skin
12 up to depths of $178.5 \pm 27.6 \mu\text{m}$ and $232.1 \pm 51.3 \mu\text{m}$, respectively. When the semi-hollow MNs were used for the transdermal
13 delivery of insulin in diabetic rats, it was observed that the blood glucose concentration (BGC) decreased remarkably
14 within 30 min, and the desired effect of insulin was maintained for an additional 3 h after the removal of insulin from the
15 skin surface. The bird-bill MN was able to load a coating gel at a maximum capacity of $3.20 \pm 0.21 \text{ mg}$ per MN array, and
16 the BGC continued to decrease significantly after MN application for up to 2–6 h. In summary, we fabricated semi-hollow
17 and bird-bill MN arrays using the injection molding method; these can be mass produced and are capable of effectively
18 producing micro-holes in the stratum corneum. The two MN arrays could provide effective transdermal delivery of large-
19 molecular-weight drugs such as insulin.

20 **Keywords** Transdermal drug delivery · Solid microneedle · Injection mold · Biocompatibility · Diabetic rat

21 Abbreviations

22 MN	Microneedle
23 SC	Stratum corneum
24 TEWL	Trans-epidermal water loss
25 MEMS	Micro-electro-mechanical system
26 STZ	Streptozotocin
27 OCT	Optical coherent tomography
28 BGC	Blood glucose concentration

29 1 Introduction

30 Microneedle (MN) arrays consist of fine needles measuring
31 several hundred micrometers (μm), and they have been
32 used to overcome some of the disadvantages associated

with conventional hypodermic or intravenous injections. 33
Based on design and usage, MNs can be classified into four 34
types as follows: hollow MNs, dissolving MNs, solid MNs, 35
and coated MNs. It is important to consider the geometries 36
(Römgens et al. 2014; Kim et al. 2018; Lahiji et al. 2019) 37
and penetration force (Cheung et al. 2014) of MNs in the 38
context of effective transdermal administration of drugs. 39
Mechanical stability of MNs is also essential for achieving 40
reliable skin penetration. Kim et al. (2018) showed that 41
obelisk-type microneedles possess better mechanical 42
stiffness than pyramidal microneedles. A solid, cone- or 43
pyramid-like MN easily opens the micropores on the surface 44
of the skin's stratum corneum (SC) (Larrañeta et al. 2016). 45

There are several advantages to MNs: skin penetration 46
enhancement occurs via a clear and persuasive mechanism; 47
hydrophilic drugs with high-molecular-weight independent of 48
physicochemical properties are absorbed through the skin; can 49
be used for self-administration; and special equipment such as a 50
power source is not required. However, one disadvantage is that 51
owing to the wound healing ability of the skin, the holes made 52
by MNs are closed over time with the aid of residual SC cells 53
in the area (unpublished data); therefore, the resulting clinical 54

A1 Tomohiro Hikima
A2 hikima@bio.kyutech.ac.jp

A3 ¹ Kyushu Institute of Technology, 680-4 Kawazu, Iizuka,
A4 Fukuoka 820-8502, Japan

A5 ² Mishima Kosan Co., Ltd, 2-1-15 Edamitsu, Yahatahigashi,
A6 Kitakyushu 805-0002, Japan

55 effect caused by the poke and patch MN may decrease over time.
 56 Concerns have been raised regarding the limited doses of coated
 57 drugs on the surface of the coated MNs (Jin et al. 2018). Hence,
 58 various shapes of coated MNs have been designed in order to
 59 increase the mass of the coated drug. Gill et al. (2008) reported
 60 that MN arrays containing 1,000 needles within a pocket could
 61 deliver 100 µg of drug into the skin. Bio-inspired, tear-drop
 62 structures on pyramidal MNs increased the liquid coating fluo-
 63 rescence intensity as high as 15 times of that seen using the
 64 non-structured MN (Plamadeala et al. 2020). In addition, the
 65 shape of the coated MN must be designed to deliver the coated
 66 drug and overcome the insertion forces into the skin.

67 Han et al. (2009) fabricated a complex-shaped MN to create
 68 sustainable micropores. As the shape of a MN array is influenced
 69 by the microfabrication method used, only simple solid MNs
 70 have been put into practical use. Micro-electro-mechanical
 71 system (MEMS) technology has been used for manufacturing
 72 the desired MN structure (Ribet et al. 2018; Ruggiero et al.
 73 2018). However, MEMS is a relatively expensive technology,
 74 considering the complicated processes involved and the
 75 requirement of several steps to fabricate high-quality MNs. In
 76 contrast, although 3D printing technology can help in developing
 77 a complex shape (Johnson et al. 2016; Economidou et al. 2019), it
 78 is not suitable for mass production of MNs. Injection molding is a
 79 technique in which a polymer is heated and kneaded in a heating
 80 cylinder to reach the fluidized state. The fluidized polymer is
 81 then pressurized and injected into the cavity of a metal casting
 82 mold, and finally cooled and solidified. Although this automated
 83 method can support mass production, the MNs thereby produced
 84 have, to date, been limited to those of a conical shape.

85 Therefore, in this study, we proposed new shapes for MNs
 86 for efficient drug delivery through the SC. In addition, we also
 87 developed a process for the inexpensive mass production of
 88 MNs of these shapes using injection molding technology. The
 89 semi-hollow MN and bird-bill MN were designed to be used to
 90 replace solid and coated MNs, respectively. The effectiveness
 91 of the two MN designs was investigated using transdermal
 92 administration of insulin, a large-molecular-weight drug, in
 93 diabetic rats.

94 **2 Materials and methods**

95 **2.1 Materials**

96 A biocompatible polymer, polycarbonate (PC; NOVAREX®, medical grade), was purchased from Mit-
 97 subishi Engineering-Plastic Co. (Tokyo, Japan). Meto-
 98 lose® (a derivative of hydroxypropyl methylcellulose; 60SH and TC-5E, medical grade) was acquired from
 99 Shin-Etsu Chemical. (Tokyo, Japan). Insulin (from bovine
 100 pancreas) was obtained from Sigma-Aldrich Co. (Tokyo,
 101 Japan). Methylene blue trihydrate (MB), streptozotocin

(STZ), and other reagents were purchased from Fujifilm 104
 Wako Pure Chemical Co. (Osaka, Japan). 105

106 **2.2 Design of MNs**

107 We designed the two MN's shapes to overcome and 107
 108 improve the disadvantages of the solid and coated MN. 108
 109 The MN arrays were designed to contain 100 needles in a 109
 110 circle with an area of 0.44 cm². The semi-hollow MN had 110
 111 a punch blade-shaped needle tip, which made the micro- 111
 112 holes on the SC for the poke and patch MN. A cross sec- 112
 113 tion of the semi-hollow MN is shown in Fig. 1a. The holes 113
 114 were expected to be maintained on the SC after the skin 114
 115 penetration, thereby enhancing the effects of the MN for 115
 116 a long-term. The bird-bill MN, used to replace the coated 116
 117 MN, had a vertical groove in its tip, which was designed 117
 118 to increase the amount of coated drugs in its groove using 118
 119 capillary attraction (Fig. 1b). The shape of the convention- 119
 120 ally coated MN was similar to a barrel when the drug was 120
 121 coated on the MN surface, and almost all of the drug on 121
 122 the needle was retained and wasted on the skin surface 122
 123 upon skin insertion. The drug in a vertical groove of the 123
 124 bird-bill MN was firmly inserted into the skin. 124

125 **2.3 Micromachining of the MN arrays**


126 The molds for this study were prepared from aluminum. 126
 127 Although, it is not a commonly used material for this pur- 127
 128 pose, it is easy to cut and pierce at the micro-scale, as 128
 129 required in this study. The MN array molds were fabri- 129
 130 cated by machining, specifically end milling. The injec- 130
 131 tion molding machine used in this study was ROBOSHOT 131
 132 S-2000i 100B (FANUC Co. Yamanashi, Japan). We used 132
 133 PC as the polymer owing to its advantages of biocompat- 133
 134 ibility and mechanical strength. 134

135 To evaluate the MN arrays, a digital microscope cam- 135
 136 era was used to capture images (PXHD30UTH, Primetech 136
 137 Engineering Co., Tokyo, Japan; and DSX510, Olympus 137
 138 Co., Tokyo, Japan). The heights and diameters of the MNs 138
 139 were measured using a shape laser microscope (VK-9710, 139
 140 Keyence Co., Osaka, Japan). 140

141 **2.4 In vitro skin insertion**

142 Miniature swine skin (Clawn strain, 1 month old) was pur- 142
 143 chased from Kagoshima Miniature Swine Research Center 143
 144 (Kagoshima, Japan). The hair on the skin samples was 144
 145 shaved and removed with a depilatory cream, and the fab- 145
 146 ricated MN array was applied on it using a spring-loaded 146
 147 applicator (5.3 m/s). The force for skin insertion by the 147
 148 applicator was approximately 17–19 N. Micropores on the 148

Fig. 1 Design of (a) a semi-hollow microneedle (MN) and (b) bird-bill MN. Photographs of semi-hollow MNs in (c) diagonal and (d) top view and bird-bill MNs in (e) side and (f) top view



149 skin were photographed using an optical coherent tomog-
 150 raphy (OCT) system (WP OCT 800-nm System, Wasatch
 151 Photonics Inc., Utah, USA). In addition, the depth of the
 152 micropores was determined using the OCT system (4 μm
 153 resolution of depth and transversal length).

154 **2.5 Coating of the bird-bill MN**

155 The bird-bill MN array was dipped in a coating gel made
 156 from Metolose® and a model drug, MB, or insulin. The
 157 coated MN was dried for 30 min at 20 °C and 50% humidity.
 158 Then, the weight of the coated MN was measured using an
 159 electronic scale. This process was repeated until the nee-
 160 dle groove was filled with the drug gel, as indicated by no
 161 further increase in weight. Insulin-coated MN arrays (7.5%
 162 insulin and 20% Metolose®) were prepared the day before
 163 the *in vivo* animal experiments and were stored at 4 °C.

164 **2.6 In vivo experiment**

165 All animal experiments were conducted in accordance with
 166 our institutional guidelines and were approved by the Ani-
 167 mal Care and Use Committee of the Kyushu Institute of
 168 Technology.

169 Rats (age, 8 weeks; weight, 266.7 ± 13.5 g; Jcl:SD strain,
 170 male; CLEA Japan Inc., Tokyo, Japan) were provided free
 171 access to food (CE-2, CLEA Japan Inc., Tokyo, Japan) and
 172 water for a week under standard conditions (temperature:
 173 23 °C, humidity: 60%, 12:12 h light:dark cycle). Before the
 174 induction of diabetes, the rats were fasted for 16 h. Each
 175 was then administered an intraperitoneal injection of STZ
 176 (65 mg/kg dissolved in ice-cold 20 mM sodium citrate
 177 buffer, pH 4.6), and fed 3 h after the injection. Subsequently,
 178 the STZ-injected rats were provided free access to food and
 179 water for over a week, and rats with a fasting blood glucose
 180 concentration (BGC) greater than 250 mg/dL, polyuria, and
 181 polydipsia were considered diabetic.

182 The hair on the dorsal skin of diabetic rats was removed
 183 48 h prior to skin piercing with the MN array using the
 184 applicator. After applying the semi-hollow MN, a cotton pad
 185 soaked with 1.0 mL insulin solution (200 IU) was loaded
 186 onto the pierced area. After 3 h, the treated area was wiped
 187 with a Kimwipe® (Nippon Paper Crexia, Co., Tokyo, Japan)
 188 and washed once with distilled water. The insulin-coated
 189 bird-bill MN was applied using the applicator and kept for
 190 1 min on the skin. The rats were fasted but provided ad libi-
 191 tum access to water for all experiments. At predetermined
 192 time points, a drop of blood was collected from the tail vein,
 193 and the BGC was measured using a Medisafe® mini GR-102
 194 (Terumo Co., Tokyo, Japan). Trans-epidermal water loss
 195 (TEWL) from the MN-treated skin was also measured using
 196 a Tewameter TM300 (Courage + Khazaka electronic GmbH,
 197 Köln, Germany). Rats treated with insulin solution (soaked

into cotton) on intact skin and stripped skin (peeling of SC
 20 times using adhesive tape) were used as negative control
 and positive control, respectively.

2.7 Statistical analysis

The arithmetic mean and standard deviation were calculated.
 A two-tailed Student’s t-test was performed to compare the
 two different conditions. A p-value less than 0.05 was con-
 sidered statistically significant.

3 Results and discussion

**3.1 Fabrication of the semi-hollow MN arrays
 and the bird-bill MN arrays**

A biodegradable polymer is better for the fabrication of
 MNs to reduce the risks associated with needle breakage
 (Lee et al. 2011). Because the mechanical aspect of MN
 is an important factor to estimate pain for insertion, we
 selected the biocompatible polymer PC. PC has a charac-
 teristic dimensional accuracy during molding, presents small
 changes in dimension after molding, and has high resistance
 to impact. Using a digital microscope, we demonstrated that
 the needles in the MN arrays did not bend or break after skin
 insertion.

Photographs of the semi-hollow MN array and the
 bird-bill MN array are shown in Fig. 1c–f, and the design
 values and actual measurements of the various parameters
 of the fabricated MNs are summarized in Table 1. The
 semi-hollow MN depth could not be measured because of
 the transparency of PC. The errors in the measured value
 (E_m) of the semi-hollow MNs with respect to the design
 values were 89.9% (height), 93.9% (top diameter), and
 99.0% (bottom diameter). The height of the MN array did
 not reach the design value. This was caused by reduced
 gate pressure and consequent insufficient degassing of
 the mold. The dimensional variation coefficients (CVs)
 of the semi-hollow MNs were as follows: 1.59×10^{-2}
 (height), 1.63×10^{-2} (top diameter) and 1.73×10^{-2}
 (bottom diameter). Thus, the semi-hollow MNs had a
 uniform shape and quality. The E_m values of the bird-
 bill MNs were 97.2% (height), 98.3% (bottom diameter),
 99.2% (groove depth), and 83.6% (groove spacing). The
 CVs were as follows: 2.98×10^{-2} (height), 2.04×10^{-2}
 (bottom diameter), 2.45×10^{-2} (groove depth), and 0.138
 (groove spacing). The groove spacing of the MN array
 was narrow when compared with the design value, and
 it had a large CV value. The number of mold parts of the
 bird-bill MN was larger than that of the semi-hollow MN.
 Thus, the gap between the parts was present in the mold
 of the bird-bill MN. Although we tried to eliminate the

Table 1 Various parameters of the fabricated microneedle (MN) arrays

	Height (μm)	Bottom diameter (μm)	Top diameter (μm)	Groove depth (μm)	Groove spacing (μm)
Design value	1,000	500	200	700	200
Semi-hollow MN	899.0 ± 14.3	494.8 ± 8.6	187.7 ± 3.1	—	—
Bird-bill MN	971.8 ± 29.0	491.4 ± 10.0	—	694.6 ± 17.0	167.2 ± 23.1

245 gap, there was still a gap in the groove of the bird-bill
 246 MN. The narrow distance between tips in the bird-bill
 247 MN was desirable to strengthen capillary attraction. We
 248 considered these results to indicate uniform quality in the
 249 arrays that were fabricated, and therefore, we used them
 250 in the following experiments.

251 3.2 Skin insertion capability of the fabricated MN 252 arrays

253 To assess the skin insertion capability of the MN arrays, the
 254 depth of each micropore after insertion of the MN array *in*
 255 *vitro* was measured using the captured OCT images (Fig. 2).
 256 Micropores were maintained at 60 min after MN application
 257 (Fig. 2c, f). The depths of the puncture holes measured from
 258 the OCT images are shown in Fig. 2g. The puncture hole
 259 depths immediately after application of the semi-hollow
 260 MNs and the bird-bill MNs were $178.5 \pm 27.6 \mu\text{m}$ and
 261 $232.1 \pm 51.3 \mu\text{m}$, respectively. These values were considered
 262 adequate to reach the capillary vessels of not only rats
 263 (Hikima et al. 2002) but also humans.

264 The time course of TEWL is shown in Fig. 3. The TEWL
 265 increased to $313 \pm 132\%$ immediately after application in the
 266 semi-hollow MN group, significantly differing from that of
 267 the control group ($p < 0.05$), and slowly decreased to base-
 268 line values over 3 h. The TEWL of the bird-bill MN group
 269 increased to $250.6 \pm 77.7\%$ after insertion and continued to
 270 maintain a high value of over 200% over 6 h. Zhou et al.
 271 (2010) reported the efficacy of transdermal insulin delivery
 272 in diabetic rats using commercially available solid MN roll-
 273 ers that pierced the skin and delivered insulin solution. It
 274 was observed that the TEWL increased two-fold after the
 275 application of MN rollers and recovered to control values
 276 within 3 h. In this study, measurements of puncture hole
 277 depth and TEWL showed that both MN arrays effectively
 278 opened the micro-holes on the SC and maintained them in
 279 that state for extended periods of time. These results indi-
 280 cated that both the fabricated MN arrays had sufficient skin-
 281 puncturing abilities.

282 3.3 Coating of the bird-bill MN arrays

283 Figure 4a shows the amount of coating gel (1% MB as
 284 a model drug and 10% Metolose®) applied during each

285 coating cycle. The amount of the coating gel increased 286
 as the coating time increased, and it reached a maximum 287
 value of $3.20 \pm 0.21 \text{ mg/MN array}$. Chen et al. (2017) 288
 reported that the maximum amount of drug coating 289
 one conical needle was 18 ng, and the total amount 290
 on the MN array (5×5) was estimated to be 450 ng. 291
 Baek et al. (2017) reported that the drug dose of the 292
 MN coated with 25% lidocaine was $290.6 \pm 45.9 \mu\text{g/MN}$ 293
 array. Therefore, it was concluded that the amount of 294
 the coated drug on the bird-bill MN was sufficiently 295
 increased, when compared with other solid MNs. 296
 Figure 4b shows a microscopic image of the insulin- 297
 coated bird-bill MN. The average weight of the coating 298
 gel on the bird-bill MN was $1.17 \pm 0.261 \text{ mg/MN array}$, 299
 and the gross weight of insulin was $93.2 \pm 12.9 \mu\text{g/MN}$ 300
 array. This was assumed to be about 23.9 mIU/MN 301
 array, which can be considered as a sufficient amount 302
 of insulin for administration to diabetic rats (Chen et al. 303
 2015; Lee et al. 2016).

304 3.4 Animal experiment

305 The BGC levels in diabetic rats subjected to SC piercing 306
 by the semi-hollow MN array were significantly 307
 decreased at all sampling time points, when compared 308
 with those of the negative controls ($p < 0.01$ or 0.05; ● 309
 in Fig. 5). After one application of the semi-hollow MN 310
 array, insulin was effective in controlling BGC within 311
 30 min and the desired effect was maintained for 6 h. 312
 The sustained hypoglycemia may also be caused by 313
 the long-term micro-holes on the SC. Insulin is rapidly 314
 absorbed through the hole, and the spot with the highest 315
 insulin concentration was created in the epidermis 316
 under the hole. After removal of the cotton pad soaked 317
 with insulin and the skin surface was wiped using a 318
 Kimwipe®, we hypothesized that insulin from the 319
 spot slowly diffused throughout the epidermis and was 320
 absorbed into the microcirculation. In comparison, the 321
 BGC in rats subjected to piercing by solid MN decreased 322
 to less than 20% after 3 h, and returned to control values 323
 after the removal of the insulin solution (300 IU/mL) 324
 (Zhou et al. 2010). This result suggests the possibility 325
 of continuous insulin delivery to the skin because of the 326
 long-term micro-hole formation by the semi-hollow MN.

Fig. 2 Real-time optical coherent tomography imaging of micropores after the application of (a–c) semi-hollow microneedle (MN) and (d–f) bird-bill MN on rat skin and (g) time course of micropore depth treated with (●) semi-hollow MN and (■) bird-bill MN. Representative images of semi-hollow MN and bird-bill MN at each time (a, d) before insertion, (b, e) 0 min and (c, f) 60 min after insertion. The data points represent the mean ± S.D. of 4 experiments (g)






Fig. 3 Time course of trans-epidermal water loss (TEWL) treated with (●) semi-hollow microneedle (MN), (■) bird-bill MN and (▲) control (intact skin without MN treatment). The data points represent the mean ± S.D. of six experiments. *: $p < 0.05$ compared to control group at the same timepoint (Student's t-test)

The BGC decreased slowly 2 h after the application of the insulin-coated bird-bill MN (23.9 mIU) and reached a value of less than 60% BGC after 6 h (■ in Fig. 5). This was caused by only one shot and 1 min application of the bird-bill MN. This may be due to the residual coating gel containing insulin in the groove that slowly dissolved for a long-term in the micropore because the coating gel did not appear to fall off from the outside surface of the needle, which was verified using a microscope. A previous study by Zhang et al. (2018) reported that when a dissolving MN containing 5 IU insulin was applied to the skin surface for more than 5 min, the hypoglycemic effect lasted for 5 h. This suggests that the bird-bill MN, which had sufficient skin-puncturing ability, increased the amount of coated insulin in the vertical groove at the MN tip and could reduce the BGC within a minute of MN application.

327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343

Fig. 4 Coating capacity on bird-bill microneedle (MN). (a) The amount of loaded gel on the bird-bill MN was measured during each coating cycle after dip coating (1% methylene blue trihydrate (MB) and 10% Metolose®). (b) Side-view photograph of the insulin-coated bird-bill MN






Fig. 5 Time course of blood glucose concentration in diabetic rats treated with (●) semi-hollow microneedle (MN), (■) bird-bill MN, (▲) negative control (insulin on the intact skin) and (Δ) positive control (insulin on the stripped skin). The data points represent the mean ± S.D. of more than 5 experiments. *: p < 0.05; **: p < 0.01, compared to the negative control at the same timepoint (Student's t-test)

4 Conclusions

We fabricated semi-hollow and bird-bill MN arrays with a mass-production capability and effective shapes for inducing micropore formation using the injection molding method. The semi-hollow MN arrays were suitable for maintaining micro-holes on the SC for an extended period. When the semi-hollow MNs were used for the transdermal delivery of insulin in diabetic rats, it was observed that the BGC decreased significantly within 30 min, and the desired effect of insulin was maintained for an additional 3 h after the

removal of insulin from the skin surface. Moreover, the bird-bill MN was able to load a coating gel at a maximum capacity of 3.20 ± 0.21 mg per MN array, and the BGC continued to decrease significantly for 2–6 h. The two MN arrays could provide effective transdermal delivery of the large-molecular-weight drug, namely insulin. Some problems may be solved by modification of the mold. The shape, number, diameter and angle of the MN, as well as the groove spacing, can be optimized to maximize the coating dose and for deeper insertion into the skin. Further studies are required to evaluate whether the developed MNs can be used for the delivery of other large-molecular-weight drugs consisting of nucleic acids and proteins.

354
355
356
357
358
359
360
361
362
363
364
365
366

Acknowledgements This work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number JP.18K12109.

367
368
369

References

S.-H. Baek, J.-H. Shin, Y.-C. Kim, Drug-coated microneedles for rapid and painless local anesthesia. *Biomed. Microdevices* **19**, 2 (2017). <https://doi.org/10.1007/s10544-016-0144-1>

M.-C. Chen, M.-H. Ling, S.J. Kusuma, Poly-γ-glutamic acid microneedles with a supporting structure design as a potential tool for transdermal delivery of insulin. *Acta Biomater.* **24**, 106–116 (2015). <https://doi.org/10.1016/j.actbio.2015.06.021>

Y. Chen, B.Z. Chen, Q.L. Wang, X. Jin, X.D. Guo, Fabrication of coated polymer microneedles for transdermal drug delivery. *J. Control Release* **265**, 14–21 (2017). <https://doi.org/10.1016/j.jconrel.2017.03.383>

K. Cheung, T. Han, D.B. Das, Effect of Force of Microneedle Insertion on the Permeability of Insulin in Skin. *J. Diabetes Sci. Technol.* **8**, 444–452 (2014). <https://doi.org/10.1177/1932296813519720>

S.N. Economidou, C.P.P. Pere, A. Reid, J. Uddim, J.F.C. Windmill, D.A. Lamprou, D. Douroumis, 3D printed microneedle patches using stereolithography (SLA) for intradermal insulin delivery.

370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387

388 Mater. Sci. Eng. C **102**, 743–755 (2019). <https://doi.org/10.1016/j.msec.2019.04.063>

389 H.S. Gill, M.R. Prausnitz, Pocketed microneedles for drug delivery to

390 the skin. *J. Phys. Chem. Solids* **69**, 1537–1541 (2008). <https://doi.org/10.1016/j.jpcs.2007.10.059>

391

392 M. Han, D.K. Kim, S.H. Kang, H.-R. Yoon, B.-Y. Kim, S.S. Lee, K.D.

393 Kim, H.G. Lee, Improvement in antigen-delivery using fabrication

394 of a grooves-embedded microneedle array. *Sens. Actuators B Chem.* **137**, 274–280 (2009). <https://doi.org/10.1016/j.snb.2008.11.017>

395

396 T. Hikima, K. Yamada, T. Kimura, H.I. Maibach, K. Tojo, Comparison

397 of skin distribution of hydrolytic activity for bioconversion of

398 β -estradiol 17-acetate between man and several animals *in vitro*.

399 *Eur. J. Pharm. Biopharm.* **54**, 155–160 (2002). [https://doi.org/10.1016/s0939-6411\(02\)00084-x](https://doi.org/10.1016/s0939-6411(02)00084-x)

400

401 X. Jin, D.D. Zhu, B.Z. Chen, M. Ashfaq, X.D. Guo, Insulin deliv-

402 ery systems combined with microneedle technology. *Adv. Drug*

403 *Deliv. Rev.* **127**, 119–137 (2018). <https://doi.org/10.1016/j.addr.2018.03.011>

404

405 A.R. Johnson, C.L. Caudill, J.R. Tumbleston, C.J. Bloomquist, K.A.

406 Moga, A. Ermoshkin, D. Shirvanyants, S.J. Mecham, J.C. Luft,

407 J.M. DeSimone, Single-Step Fabrication of Computationally

408 Designed Microneedles by Continuous Liquid Interface Produc-

409 tion. *PLoS One* **11**(2016)

410

411 M.J. Kim, S.C. Park, B. Rizal, G. Guanes, S.-K. Baek, J.-H. Park, A.R.

412 Betz, S.-O. Choi, Fabrication of Circular Obelisk-Type Multilayer

413 Microneedles Using Micro-Milling and Spray Deposition. *Front.*

414 *Bioeng. Biotechnol.* **6**, 54 (2018). <https://doi.org/10.3389/fbioe.2018.00054>

415

416 S.F. Lahiji, Y. Kim, G. Kang, S. Kim, S. Lee, H. Jung, Tissue Interlock-

417 ing Dissolving Microneedles for Accurate and Efficient Transder-

418 mal Delivery of Biomolecules. *Sci. Rep.* **9**, 7886 (2019). <https://doi.org/10.1038/s41598-019-44418-6>

419

420 E. Larrañeta, R.E.M. Lutton, A.D. Woolfson, R.F. Donnelly, Micronee-

421 dle arrays as transdermal and intradermal drug delivery systems:

422 Materials science, manufacture and commercial development.

423 *Mater. Sci. Eng. R* **104**, 1–32 (2016). <https://doi.org/10.1016/j.mser.2016.03.001>

424

425 I.-C. Lee, W.-M. Lin, J.-C. Shu, S.-W. Tsai, C.-H. Chen, M.-T. Tsai, 426

427 Formulation of two-layer dissolving polymeric microneedle 428

429 patches for insulin transdermal delivery in diabetic mice. *J. 430*

431 *Biomed. Mater. Res. A* **105**, 84–93 (2016). <https://doi.org/10.1002/jbm.a.35869>

432

433 K. Lee, C.Y. Lee, H. Jung, Dissolving microneedles for transdermal 434

435 drug administration prepared by stepwise controlled drawing of 436

437 maltose. *Biomaterials* **32**, 3134–3140 (2011). <https://doi.org/10.1016/j.biomaterials.2011.01.014>

438

439 C. Plamadeala, S.R. Gosain, F. Hischen, B. Buchroithner, S. 440

441 Puthukodan, J. Jacak, A. Bocchino, D. Whelan, C. O'Mahony, 442

443 W. Baumgartner, J. Heitz, Bio-inspired microneedle design for 444

445 efficient drug/vaccine coating. *Biomed. Microdevices* **22**, 8 446

447 (2020). <https://doi.org/10.1007/s10544-019-0456-z>

448

449 F. Ribet, G. Stemme, N. Roxhed, Real-time intradermal continuous 450

451 glucose monitoring using a minimally invasive microneedle-based 452

453 system. *Biomed. Microdevices* **20**, 101 (2018). <https://doi.org/10.1007/s10544-018-0349-6>

454

455 A.M. Römgens, D.L. Bader, J.A. Bouwstra, F.P. Baaijens, C.W.J. 456

457 Oomens, Monitoring the penetration process of single micronee- 458

459 dles with varying tip diameters. *J. Mech. Behav. Biomed Mater.* 460

461 **40**, 397–405 (2014). <https://doi.org/10.1016/j.jmbbm.2014.09.015>

462

463 F. Ruggiero, R. Vecchione, S. Bhowmick, G. Coppola, S. Coppola, E. 464

465 Esposito, V. Lettera, P. Ferraro, P.A. Netti, Electro-drawn polymer 466

467 microneedle arrays with controlled shape and dimension. *Sens. 468*

469 *Actuators B. Chem.* **255**, 1553–1560 (2018). <https://doi.org/10.1016/j.snb.2017.08.165>

470

471 Y. Zhang, G. Jiang, W. Yu, D. Liu, B. Xu, Microneedles fabricated 472

473 from alginate and maltose for transdermal delivery of insulin on 474

475 diabetic rats. *Mater. Sci. Eng. C* **85**, 18–26 (2018). <https://doi.org/10.1016/j.msec.2017.12.006>

476

477 C.-P. Zhou, Y.-L. Liu, H.-L. Wang, P.-X. Zhang, J.-L. Zhang, Trans- 478

479 dermal delivery of insulin using microneedle rollers *in vivo*. *Int. 480*

481 *J. Pharm.* **392**, 127–133 (2010). <https://doi.org/10.1016/j.ijpharm.2010.03.041>

482

483 **Publisher's Note** Springer Nature remains neutral with regard to 461

462 jurisdictional claims in published maps and institutional affiliations.